The present findings establish that although the expression of a tumour-specific antigen is necessary for the induction of immuno-protection against tumour-cell challenge, this alone is not a sufficient condition for eliciting tumour immunity.
The present findings establish that although the expression of a tumour-specific antigen is necessary for the induction of immuno-protection against tumour-cell challenge, this alone is not a sufficient condition for eliciting tumour immunity. THE ATTENUATION of tumour cells by chemical treatment before using them as immunogens has been considered attractive from several viewpoints (Prager & Baechtel, 1973; Sanderson & Frost, 1974; Staab & Anderer, 1977) , particularly since previous studies have indicated that immunization with chemically modified antigens, such as flagellin, results in enhanced cell-mediated immunity and depressed antibody responses (e.g. Parish & Liew, 1972) . Chemical modification may be performed with a high degree of reproducibility, and it is possible to ensure that all cells are rendered inviable. It may be further argued that, by presenting an animal with a chemically attenuated tumour cell, the reactivity against tumourassociated antigens may be enhanced by responses against new determinants introduced by the chemical modification. Indeed, this notion has been supported by experimental evidence ever since Landsteiner (1945) demonstrated that antibodies induced by immunization with conjugated protein had a broad range of specificities. These were determined to be directed against (a) the conjugated group or hapten, (b) determinants of the carrier protein and (c) new determinants composed of the hapten and a portion of the carrier. Other mechanisms have been proposed by which chemical modification may enhance immunogenicity, but without invoking the requisite of the introduction of new groups (Mitchison, 1] 
970).
In the present studies, the effects of glutaraldehyde cross-linking of the cell surface of an aminoazodye-induced rat hepatoma (D23) have been investigated. This tumour is characterized by the expression of a tumour-specific rejection antigen against which it is possible to induce moderate levels of immunoprotection when y-irradiated tumour cells are used as immunogen (Baldwin & Barker, 1967a; Price et al., 1978) . Subeellular preparations or soluble antigen isolated from this hepatoma are generally ineffective in inducing resistance to tumour challenge except when administered within a restricted dose range (Price & Baldwin, 1974; Price et al., 1978) . The initial hypothesis considered was to explore whether stabilization of the cell surface with glutaraldehyde as a cross-linking reagent increased or modified the immunogenicity of the tumour, the view being that such treated cells would represent a more persistent immunogen. For this purpose, y-irradiated hepatoma cells as an immunogen of defined efficacy were treated with glutaraldehyde at various concentrations and their immunogenicity and expression of surface antigens were evaluated.
MATERIALS AND METHODS
Animals, tumours and sera.-Inbred WAB/ Not (Nottingham Cancer Research Campaign Laboratory subline of WAB) and KX/Not (Nottingham Cancer Research Campaign Laboratory subline of KX) rats were maintained by single-line brother-sister mating. Hepatomas D23 and D30, induced by oral administration of 4-dimethylaminoazobenzene, were maintained by serial s.c. passage in WAB/Not rats. Hepatoma D23-and D30-bearer sera were from donors bearing i.p. 9-day implants established by injection of tumour mince (Price & Baldwin, 1977) . Hepatoma D23-and D30-immune sera were prepared in syngeneic rats by implantation of y-irradiated (15,000R) grafts of tumour. A KX/Not anti-WAB/Not alloantiserum was prepared by s.c. implantation of hepatoma D23 grafts in male KX/Not rats. Serum donors were bled by cardiac puncture under ether anaesthesia, and the serum was collected and stored at -20°C.
Irradiation of hepatoma D23 cells.-Singlecell suspensions of hepatoma D23 were prepared by trypsinization of tumour mince and suspended in Hanks' balanced salt solution (HBSS) (Baldwin & Barker, 1967b figure, and values of 0-3 or greater were taken to represent a significant membrane immunofluorescence staining reaction (Baldwin & Barker, 1967b 5IChromiumn-release test.-This was performed according to a previously described microassay procedure (Price, 1978) .
125I-Labelling of cells.-Hepatoma cell surfaces were radioiodinated according to the method of Phillips & Morrison (1971) .
Briefly, 200 ,tCi Na125J was added to glutaraldehyde-treated or untreated hepatoma cells (1 ml at 107 cells/ml in PBS). To this 50 ,ug lactoperoxidase (Sigma Chemical Co., Kingston upon Thames, England) and 25 ,ul of 0-03% H202 in PBS was added. The cells were kept at room temperature for 10 min and a further 25 ,ul of 0-03% H202 was added. After 10 min, the cells were diluted to 25 ml with PBS and washed x 4 by centrifugation with PBS. The final pellet was suspended in 4 ml of 2% sodium dodecyl sulphate (SDS) containing 2% /3-mercaptoethanol, which was heated to 100°C for 5 min. The resulting solution was dialysed against 0.1% SDS, 0.1% 3-mercaptoethanol in OO1m sodium phosphate buffer, pH 7-0, for 18 h. Aliquots of the SDS-solubilized cells were separated by analytical polyacrylamidegel electrophoresis upon 10% acrylamide gels according to the method of Weber & Osborn (1969) . Gels were cut into 2 mm slices which were individually counted in an LKBWallac Gamma Counter.
RESULTS
In a preliminary experiment, the dose and timing of i.p. immunization with y-irradiated hepatoma D23 cells was investigated. As shown in Table I , treatment of rats with a single injection of 106 immunizing cells from between 28 days before s.c. tumour-cell challenge and 7 days after challenge was ineffective in modifying the incidence of tumours. Immunization with 107 irradiated cells at 7 and 14 days before challenge provided protection against tumour growth and, using the highest immunizing dose of 108 cells, resistance against challenge was evident in all groups of rats receiving immunization up to 28 days before challenge. In no case was it possible significantly to modify the incidence of tumours when treatment was given after tumour-cell challenge (Table I) .
In subsequent experiments, when glutaraldehyde y-irradiated cells were used as the immunogen, a single dose of ' 2-5 x 107 cells was given 7 days before s.c. tumourcell challenge with between 1 x 103 and I y-irradiated cells were pretreated for 30 min with glutaraldehyde or, in controls, PBS at room temperature, and they were washed twice by centrifugation with HBSS before injection.
§ NT Not tested. Table II shows the results of 3 experiments in which the effect of treating y-irradiated D23 cells with glutaraldehyde was analysed by determining their capacity to induce immunoprotection against a challenge with D23 cells. It is evident that in rats receiving D23 cells treated with glutaraldehyde at concentrations as low as 0.01% (and in one case 0-001%), the tumour incidence was essentially the same as that in untreated control animals. This contrasts with the result of immunizing rats with y-irradiated hepatoma cells treated with either PBS or with glutaraldehyde at concentrations lower than 0.001 %, when a reduced tumour incidence was apparent.
The humoral response to immunization with glutaraldehyde-treated and untreated y-irradiated D23 cells, as assessed by the indirect membrane-immunofluorescence test, is shown in Table III . The only group of rats exhibiting a significant membraneimmunofluorescence reaction with sera, giving a fluorescence index >03, was the group immunized by 4 weekly i.p. injections of untreated, y-irradiated D23 cells (Group 2, Table III ). The capacity of these cells to induce specific antibody production was abolished by pretreatment with glutaraldehyde at concentrations of 0-001 and 0-01% (Groups 3 and 4, respectively; Table III) .
Although these results suggest that the activity of the tumour-specific antigen associated with D23 is lost or significantly diminished when assayed by the induction of immune responses, the results in Table  IV indicate that glutaraldehyde-treated y-irradiated D23 cells still retain a serologically identifiable tumour-specific antigen when assessed in membrane-immunofluorescence tests. In these experiments, D23 immune or bearer serum (containing antibody specifically reactive with D23 cells (Baldwin & Barker, 1967a; Price & Baldwin, 1977) (Table IV) . That glutaraldehyde failed to modify the reactivity of D23-specific antigen in in vitro tests is further confirmed in Tables V and VI. These tests showed that absorption of sera containing specific antibody to D23 with glutaraldehydetreated and untreated D23 cells removed their reactivity for D23 target cells, as assessed by the indirect membraneimmunofluorescence test (Table V) and by complement-dependent cytotoxicity assays using a 51Cr-release test (Table VI) . Exposure of cells to concentrations of glutaraldehyde as high as 0-5% did not modify their capacity to remove tumourspecific antibodies. However, when these sera were absorbed with treated or untreated D30 cells, their reactivities for D23 cells by immunofluorescence (Table  V) or complement-dependent cytotoxicity (Table VI) were equal, and in all cases comparable to those of unabsorbed sera.
It is clear from the data in Table IV that KX/Not anti-WAB/Not alloantigens associated with D23 were largely unaffected by treatment with glutaraldehyde, since this alloantiserum reacted strongly with treated and untreated target cells, giving in all instances a fluorescence index of 10. This conclusion was substantiated by a more quantitative radioisotopic antiglobulin assay using an 1251-labelled F(ab')2 fragment of the antibody from a sheep anti-rat IgG serum to reveal cellsurface-bound rat immunoglobulin on D23 cells. As shown in Table VII , the uptake of the antiglobulin reagent was essentially equal with both untreated D23 cells and with D23 cells treated with 04 % glutaraldehyde, which had been exposed to normal or alloantiserum at dilutions of 1/100, 1/500 and 1/1000. At each of these dilutions the uptake of radiolabel in cells exposed to alloantiserum was considerably greater than in cells exposed to normal serum at the same dilution, or medium alone (Table VII) . Although KX/Not anti-WAB/Not alloantigens were still expressed on D23 cells treated with glutaraldehyde, these cells did not induce alloantibody formation in KX/Not rats as assayed by either the indirect membraneimmunofluorescence test of the radioisotopic antiglobulin assay. As shown in Table VIII, (Bubbers & Henney, 1975 One important factor influiencing the immunogenicity of living allogeneic cells has been shown to be the metabolic state of the cells. Indeed, for the in vitro induction of cell-mediated cytolysis an active cell metabolism was required, one interpretation being that protein turnover at the cell surface was necessary for the full expression of immunogenicity (Wagner, 1973) . To what extent the irradiated hepatoma cells used in the present studies retain an active cell metabolism, albeit for a limited period, is the subject of a later report (Dennick et al., 1979) . The effects of glutaraldehyde on cell metabolism are profound, and in one study it was found that treatment with 0 1 500 glutaraldehyde for only 10 s destroyed cells' ability to incorporate amino acids or nucleotides into macromolecules (Bubbers & Henney, 1975) . Certainly the conditions used in the present investigation, involving treatment for 30 min, would be sufficient to modify the efficiency of the cell's synthetic apparatus. Indeed, the conditions of treatment were sufficient to markedly cross-link much of the surface protein, as demonstrated by the polyacrylamide-gel electrophoresis of radioiodinated, glutaraldehydetreated hepatoma cells (Fig. 1) . In these tests, with increasing glutaraldehyde concentrations, more of the labelled material was covalently linked into insoluble highmol.-wt aggregates which failed to enter the polvaervlamide gel. However, whether there is any parallel between the extent of cross-linking and the reduction in immunogenicity remains to be seen. Also, with other tumour models it has been possible to use various chemical treatments, including the use of cross-linking reagents, for the attenuation of viable tumour cells with retention of demonstrable levels of immunogenicity (Prager & Baechtel, 1973) .
Finally, while the glutaraldehyde-fixed cell (expressing the tumour-specific antigen on an essentially inert carrier) may represent a more persistent immunogen, such material may not however be accessible to effective macrophage processing.
The processing of different materials such as soluble and particulate antigens is known to differ (Unanue, 1972) and if macrophage degradation of multideterminant cellular antigen is necessary for the induction of immunity (Brunda & Raffel, 1977) clearly the fixed cell as an immunogen would be far less amenable to these processes than the unfixed cell.
